Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 94 of 1,261
  1. US 12091462

    Antibodies binding to vista at acidic pH

    Five Prime Therapeutics, Inc. Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  2. US 12090170

    Methods of treating glioblastomas

    The Regents of the University of California Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  3. US 12091661

    Organic compositions to treat HSF1-related diseases

    Arrowhead Pharmaceuticals, Inc. Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  4. US 12091666

    Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  5. US 12090145

    Combination therapy for treating or preventing depression or other mood diseases

    United States Government as represented by the Department of Veterans Affairs Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  6. US 12083122

    Laureth-4 containing topical formulations

    ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Sep 10, 2024 Β· Expires Sep 5, 2044

    granted
  7. US 12083227

    Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis

    Neurocrine Biosciences, Inc. Β· Granted Sep 10, 2024 Β· Expires Sep 5, 2044

    granted
  8. US 12083141

    Treatment of hyperglycemia with solute carrier family 39 member 5 (SLC39A5) inhibitors

    REGENERON PHARMACEUTICALS, INC. Β· Granted Sep 10, 2024 Β· Expires Sep 5, 2044

    granted
  9. US 12083184

    Hydrogel prodrug for treatment

    Viking Scientific, Inc. Β· Granted Sep 10, 2024 Β· Expires Sep 5, 2044

    granted
  10. US 12083192

    Methods for treatment of patients with myelodysplastic syndromes

    Actinium Phamaceuticals, Inc. Β· Granted Sep 10, 2024 Β· Expires Sep 5, 2044

    granted
  11. US 12084489

    Antibodies and methods for the diagnosis, prevention, and treatment of Epstein Barr virus infection

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Sep 10, 2024 Β· Expires Sep 5, 2044

    granted
  12. US 12084727

    Microbiome markers and therapies for autism spectrum disorders

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Sep 10, 2024 Β· Expires Sep 5, 2044

    granted
  13. US 12084490

    Antibody based reagents that specifically recognize toxic oligomeric forms of tau

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Sep 10, 2024 Β· Expires Sep 5, 2044

    granted
  14. US 12082565

    Non-human animals models of retinoschisis

    REGENERON PHARMACEUTICALS, INC. Β· Granted Sep 10, 2024 Β· Expires Sep 5, 2044

    granted
  15. US 12084403

    Linkers for antibody drug conjugates

    The Board of Regents of the University of Texas System Β· Granted Sep 10, 2024 Β· Expires Sep 5, 2044

    granted
  16. US 12084514

    Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof

    The Board of Regents of the University of Oklahoma Β· Granted Sep 10, 2024 Β· Expires Sep 5, 2044

    granted
  17. US 12084431

    Pharmaceutical salts of pyrimidine derivatives and method of treating disorders

    Takeda Pharmaceutical Company Limited Β· Granted Sep 10, 2024 Β· Expires Sep 5, 2044

    granted
  18. US 12084436

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited Β· Granted Sep 10, 2024 Β· Expires Sep 5, 2044

    granted
  19. US 12084438

    GCN2 inhibitors and uses thereof

    Vertex Pharmaceuticals Incorporated Β· Granted Sep 10, 2024 Β· Expires Sep 5, 2044

    granted
  20. US 12083151

    Synergistic bacterial compositions and methods of production and use thereof

    Seres Therapeutics, Inc. Β· Granted Sep 10, 2024 Β· Expires Sep 5, 2044

    granted
  21. US 12084677

    Methods of recellularizing a tissue or organ for improved transplantability

    Regents of the University of Minnesota Β· Granted Sep 10, 2024 Β· Expires Sep 5, 2044

    granted
  22. US 12083230

    Nano-encapsulation using GRAS materials and applications thereof

    THE TRUSTEES OF PRINCETON UNIVERSITY Β· Granted Sep 10, 2024 Β· Expires Sep 5, 2044

    granted
  23. US 12083229

    Ocular drug delivery formulation

    INMED PHARMACEUTICALS INC. Β· Granted Sep 10, 2024 Β· Expires Sep 5, 2044

    granted
  24. US 12084447

    SHP2 phosphatase inhibitors and methods of use thereof

    Relay Therapeutics, Inc. Β· Granted Sep 10, 2024 Β· Expires Sep 5, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.